sinopharm group co. ltd. - SHTDF

SHTDF

Close Chg Chg %
2.60 -0.13 -4.81%

Closed Market

2.48

-0.13 (4.81%)

Volume: 600.00

Last Updated:

Jan 5, 2026, 11:00 AM EDT

Company Overview: sinopharm group co. ltd. - SHTDF

SHTDF Key Data

Open

$2.60

Day Range

2.48 - 2.60

52 Week Range

2.11 - 2.60

Market Cap

$8.21B

Shares Outstanding

3.12B

Public Float

1.34B

Beta

0.28

Rev. Per Employee

N/A

P/E Ratio

8.68

EPS

N/A

Yield

361.52%

Dividend

$0.09

EX-DIVIDEND DATE

Jun 16, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

13.84K

 

SHTDF Performance

1 Week
 
0.00%
 
1 Month
 
-1.98%
 
3 Months
 
3.13%
 
1 Year
 
-0.70%
 
5 Years
 
N/A
 

SHTDF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About sinopharm group co. ltd. - SHTDF

Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. It operates through the following business segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers and other suppliers. The Medical Devices segment consists of the distribution of medical devices in China. The Retail Pharmacy segment refers to the network of retail drug stores in major cities of China via direct operations and franchises. The Other Business segment comprises of the production and sale of pharmaceutical products, chemical reagents and laboratory supplies. The company was founded on January 8, 2003 and is headquartered in Shanghai, China.

SHTDF At a Glance

Sinopharm Group Co., Ltd.
Sinopharm Group Building
Shanghai, Shanghai 200023
Phone 86-21-6321-1750 Revenue 81.22B
Industry Medical Distributors Net Income 979.56M
Sector Distribution Services Employees 108,217
Fiscal Year-end 12 / 2025
View SEC Filings

SHTDF Valuation

P/E Current 8.681
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 8.735
Price to Sales Ratio 0.105
Price to Book Ratio 0.792
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 7.082
Enterprise Value to Sales 0.267
Total Debt to Enterprise Value 0.727

SHTDF Efficiency

Revenue/Employee 750,506.44
Income Per Employee 9,051.772
Receivables Turnover 2.824
Total Asset Turnover 1.506

SHTDF Liquidity

Current Ratio 1.388
Quick Ratio 1.139
Cash Ratio 0.268

SHTDF Profitability

Gross Margin 7.257
Operating Margin 2.959
Pretax Margin 2.19
Net Margin 1.206
Return on Assets 1.816
Return on Equity 9.188
Return on Total Capital 3.687
Return on Invested Capital 7.717

SHTDF Capital Structure

Total Debt to Total Equity 145.841
Total Debt to Total Capital 59.323
Total Debt to Total Assets 29.286
Long-Term Debt to Equity 15.081
Long-Term Debt to Total Capital 6.134
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sinopharm Group Co. Ltd. - SHTDF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
80.79B 82.00B 84.20B 81.22B
Sales Growth
+22.18% +1.49% +2.69% -3.54%
Cost of Goods Sold (COGS) incl D&A
74.22B 75.22B 77.61B 75.32B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
608.13M 618.53M 625.30M 657.75M
Depreciation
548.95M 560.52M 566.59M 596.36M
Amortization of Intangibles
59.18M 58.02M 58.71M 61.39M
COGS Growth
+22.65% +1.34% +3.18% -2.94%
Gross Income
6.57B 6.78B 6.59B 5.89B
Gross Income Growth
+17.10% +3.24% -2.76% -10.60%
Gross Profit Margin
+8.13% +8.27% +7.83% +7.26%
2021 2022 2023 2024 5-year trend
SG&A Expense
3.42B 3.50B 3.53B 3.49B
Research & Development
- - - -
-
Other SG&A
3.42B 3.50B 3.53B 3.49B
SGA Growth
+16.20% +2.26% +0.83% -1.04%
Other Operating Expense
- - (1.96M) 26.86M
-
Unusual Expense
81.71M 3.22M (14.27M) 148.91M
EBIT after Unusual Expense
3.07B 3.25B 3.08B 2.25B
Non Operating Income/Expense
18.11M (99.06M) (34.29M) (66.60M)
Non-Operating Interest Income
86.61M 80.60M 104.92M 85.73M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
614.24M 554.34M 447.95M 409.24M
Interest Expense Growth
+17.10% -9.75% -19.19% -8.64%
Gross Interest Expense
616.65M 557.54M 450.78M 410.26M
Interest Capitalized
2.41M 3.20M 2.83M 1.02M
Pretax Income
2.47B 2.60B 2.60B 1.78B
Pretax Income Growth
+16.71% +5.18% -0.03% -31.53%
Pretax Margin
+3.06% +3.17% +3.09% +2.19%
Income Tax
610.66M 626.46M 635.47M 497.07M
Income Tax - Current - Domestic
657.00M 665.28M 656.39M 577.50M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(46.33M) (38.83M) (20.92M) (80.43M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.03B 2.13B 2.12B 1.45B
Minority Interest Expense
822.74M 864.28M 840.66M 468.81M
Net Income
1.20B 1.27B 1.28B 979.56M
Net Income Growth
+15.53% +5.25% +0.93% -23.34%
Net Margin Growth
+1.49% +1.54% +1.52% +1.21%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.20B 1.27B 1.28B 979.56M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.20B 1.27B 1.28B 979.56M
EPS (Basic)
0.3855 0.4057 0.4095 0.3139
EPS (Basic) Growth
+15.18% +5.24% +0.94% -23.35%
Basic Shares Outstanding
3.12B 3.12B 3.12B 3.12B
EPS (Diluted)
0.3855 0.4057 0.4095 0.3139
EPS (Diluted) Growth
+15.18% +5.24% +0.94% -23.35%
Diluted Shares Outstanding
3.12B 3.12B 3.12B 3.12B
EBITDA
3.76B 3.87B 3.69B 3.06B
EBITDA Growth
+18.34% +3.12% -4.71% -17.06%
EBITDA Margin
+4.65% +4.72% +4.38% +3.77%

Sinopharm Group Co. Ltd. in the News